Mainz Biomed B.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYNZ research report →
Price Chart
About the company
Mainz Biomed B. V. is a German company specializing in molecular genetics for the development of cancer diagnostics.
- CEO
- Guido Baechler
- IPO
- 2021
- Employees
- 19
- HQ
- Mainz, DE
Get TickerSpark's AI analysis on MYNZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.69M
- P/E
- -0.69
- Fwd P/E
- 10.26
- PEG
- 0.01
- P/S
- 117.31
- P/B
- 1.24
- EV/EBITDA
- -1.23
- Div Yield
- 0.00%
- Gross Margin
- 79.97%
- Op Margin
- -8148.16%
- Net Margin
- -9572.20%
- ROE
- -365.38%
- ROIC
- -99.36%
Latest fiscal year · YoY change
- Revenue
- $537.08K-39.9%
- Gross Profit
- $-225,928-139.3%
- Op Income
- $-13,498,818
- Net Income
- $-16,210,718+25.1%
- EPS
- $-2.70+87.9%
- OCF Growth
- +35.8%
- FCF Growth
- +36.7%
- 52W High
- $5.34
- 52W Low
- $0.55
- 50D MA
- $0.97
- 200D MA
- $1.38
- Beta
- 0.32
- RSI (14)
- 43
- Avg Volume
- 554.37K
No earnings-call transcripts are available for MYNZ yet.
- Free Float
- 84.5%
- Shares Outstanding
- 4.09M
- Float Shares
- 3.46M
of shares held by institutions
18 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Greenwich Investment Management, Inc. | 10.86K | ▼ 1.13K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Ben-Tzvi Avraham | other | 137,141 |
| May 8, 26 | NATAN DAVID | other | 137,141 |
| Apr 22, 26 | Lazar David E. | other | 1,000,000 |
| Apr 22, 26 | Lazar David E. | other | 1,000,000 |
| Feb 13, 26 | Lazar David E. | other | 1,000,000 |
| Feb 13, 26 | Lazar David E. | other | 1,000,000 |
| Feb 13, 26 | Lazar David E. | other | 1,000,000 |
| Feb 13, 26 | Lazar David E. | other | 0 |
| Feb 13, 26 | Caragol William J | other | 290,000 |
| Feb 13, 26 | Dreismann Heinrich | other | 45,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MYNZ coverage
Recent articles, reports, and earnings notes.
No research on MYNZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYNZ report →Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
globenewswire.com · Mar 13
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
globenewswire.com · Mar 11
Mainz Biomed NV (NASDAQ:MYNZ) Short Interest Update
defenseworld.net · Feb 1
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
globenewswire.com · Jan 14
2 Small-Cap Biotechs That Could Reward Patient Investors
marketbeat.com · Dec 12
Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?
defenseworld.net · Nov 22
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
globenewswire.com · Nov 18
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
globenewswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.